Inclisiran is recommended as an option for the secondary prevention of the treatment of primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet in adults with a history of established cardiovascular disease whose LDL cholesterol concentrations are persistently 2.6mmol/l or more despite maximum tolerated lipid-lowering therapy.